Strategy You Need,
Results You Desire
November 7th – 8th 2022
Boston, USA
November 7th – 8th 2022
Boston, USA
Meridian Drug Discovery is a bi-annual event series from Continuum Globe Ltd. A platform for scientific knowledge sharing and a business incubator for vendor-sponsor meetings. MDD helps in networking, knowledge sharing, and partner outreach.
Our team partners with leading research institutions, private pharma-biotechs, and contract research organizations to publish the latest scientific and technological breakthroughs.
Meridian Drug Discovery helps companies improve their study design and overall strategy for hit discovery, validation, and research. For the 5th Meridian Drug Discovery, we have centralized our scientific approach to Artificial Intelligence, AI-driven drug design, drug safety, advanced lead selection, and more.
days
hours
minutes
seconds
Principal Scientist
Senior Computational Scientist with 18 years of experience in developing sophisticated, analytical, bioinformatics algorithms, pipelines, and portals as well as applying them to understand complex biological data.
Credo: the properly conducted analysis of combined clinical, molecular and genomic data can be easily translated into clinical applications to increase the success rate of drug developments and to provide personalized medicine solutions to patients.
Chief Scientific Officer, Executive Chairman of Board of Directors
Dr. Lippa has served as Executive Chairman since March, 2013 and Chief Scientific Officer since August, 2015. From March, 2013 until August, 2015 and from September, 2018 until May, 2020, he also served as President and Chief Executive Officer, respectively.
He is a Senior Managing Director and founder of T Morgen Capital LLC through which he administers his family’s assets. T Morgen Capital LLC is a significant equity owner and managing member of Aurora Capital LLC (“Aurora”), a firm of which Mr. Margolis is the president and founder and which has served as a placement agent with respect to certain of the Company’s prior financings. Aurora was SEC registered and a FINRA member firm until voluntarily withdrawing effective July 2021 and has been inactive in the securities and investment banking industry since April 2021.
Dr. Lippa and Mr. Margolis founded and jointly manage, since 2004, Atypical BioCapital Management LLC and Atypical BioVentures Fund LLC, a life sciences fund management company and venture fund, respectively. Both entities are currently inactive. Dr. Lippa is a member of the Board of Directors of ContraVir Pharmaceuticals, Inc. since December 2015, where he is a member of the audit committee and the compensation committee. Dr. Lippa was co-founder of DOV Pharmaceutical, Inc., where he served as Chairman of the Board and Chief Executive Officer from its inception in 1995 through 2005 and which he took public in 2002.
Associate Director
Experienced techno-functional leader with demonstrated history of empirical contributions to Consumer Health, Healthcare, Pharmaceuticals, Research Laboratories, Automotive & Aerospace Domains
Highly organized, self-motivated, innovative and science-driven strategist with working experiences as Director, Delivery Manager, Solutions Architect, Lab Informatics (LIMS/ELN), Development & Applications Maintenance for R&D systems.
Well-versed in working with diverse cultures providing effective & tangible outcomes through smart directional leadership. Always embracing & measuring team goals for OKR’s [Objectives and Key Results]
CEO
Margaret K. Offermann, MD, PhD is a medical oncologist, tumor biologist, educator and executive with professional experience in academic, philanthropic and private sectors. She is the CEO of OncoSpherix, a preclinical stage cancer drug development company that is advancing a first-in-class family of small molecules that block the ability of cancer cells to adapt and spread from regions of low oxygen that results from growing faster than the blood supply.
Dr. Offermann previously served as Managing Partner of the Salutramed Group (a boutique C-level consulting group), Deputy National Vice President for Research at the American Cancer Society and Professor of Hematology and Oncology at Emory University, where she served as co-director of the MD, PhD training program, Associate Director of the Postgraduate Training Program in Hematology and Oncology and Associate Director of the Winship Cancer Institute.
She has served in executive roles with numerous non-profit organizations, including serving as President of the Federation of American Societies for Experimental Biology (FASEB), a federation of 30 non-profit research societies with over 130,000 members that advances biological science through collaborative advocacy for research policies that promote scientific progress and education.
President & CEO
John Lu is currently the President and CEO of HebeCell Corporation. Established in April of 2016, HebeCell focuses on the fields of Immunotherapy and Regenerative Medicine. Our mission is to develop and commercialize human iPSC-based cell therapeutics for multiple human diseases.
HebeCell has developed a platform technology using a scalable 3-D bioreactor system for the expansion and differentiation of human iPSCs towards immune and other lineages. Based on this 3D platform, HebeCell currently has two ongoing programs: 1) Immunotherapy Program: human iPSC-derived off-the-shelf CAR-NK Cells for the treatment of multiple tumours including blood and solid tumours, as well as autoimmune and infectious diseases; 2) Ocular Program: human iPSC-derived photoreceptor progenitors for the treatment of macular degeneration including Retinitis Pigmentosa, Stargardt’s Disease and Age-related Macular Degeneration (AMD).
Before establishing HebeCell, John was the Senior Director of Research at Advanced Cell Technology/Ocata Therapeutics from 2005 to 2016, which was acquired by Astellas in 2016, the 2nd largest pharmaceutical company in Japan. During his tenure at ACT/Ocata, John developed the hemangioblast, red blood cell, MK/platelet and MSC programs, as well as photoreceptor and retinal ganglion cell programs.
Director, Biologics Device Development
Medical device and drug-device combination product development leader, engineering director, manufacturing manager and experienced in working across functions and business groups in varying organizations. Have successfully brought new and effective products to market throughout the world, and developed and implemented new engineering, quality control and manufacturing processes. Lead Product Development, and Engineering teams.
Highly experienced and proficient in engineering and project management activities: strategic planning, design engineering, manufacturing engineering, design control, prioritization, contract engineering management, resource allocation, new product and process development.
Specialties: Product development, project leadership and project management, combination product medical devices, laboratory process automation, regulatory standards and process, cross-functional communication, engineering management, product development
Chief Scientific Officer
Over a decade of experience in identifying unique differentiated opportunities, and building/implementing plans and teams to create value for commercial success. Significant expertise in leading cross-functional teams in the deployment of AI analytics/machine learning integration to domain-specific RWD/RWE environments enabling rapid, synchronous translation of early discovery R&D, target tractability, drug discovery & pharmaceutical development. Reputation for creativity, innovation, critical thinking and ability to deliver with strong scientific expertise in translational sciences.
Chief Scientific Officer
Dr. Xia has more than 30 years of experience in the research and development of therapeutic antibodies, from early validation through pre-clinical development. His previous positions include Head of Biotherapeutics at Moderna, where he focused on the discovery of immuno-oncology, autoimmune, and infectious disease therapeutics, Director at Synageva BioPharma, where he was responsible for early biologics discovery in rare and orphan diseases, and Pfizer, where he served in a variety of scientific roles, leading teams in immuno-oncology target identification and validation and bi- and multi-specific antibody design and development.
He has also served as an Instructor at Dana Farber Cancer Institute and Harvard Medical School, having completed a post-doctoral fellowship in immunology at Harvard Medical School following receipt of his PhD in Immunology and Molecular Biology from the University of Kentucky. His efforts have been recognized globally, receiving the NIH National Research Service Award in 1994, an AAPS award (New York) in 2001, and having been named an Outstanding Alumnus of China Pharmaceutical University in 2016.
Our stage is open for companies to present their case studies, research, and new technological, scientific, or business breakthroughs. Research that helps to bring new cures or anything that reduces the cost or timeline in bringing that cure to the public.
Our speaking faculty is hand-picked from leading pharma-biotech, CRO, Regulatory, Research Institutes, & governmental organizations.
We keep a healthy and relevant attendee to maintain the quality and Sponsor-CRO ratio in balance.
It’s our way to give back to the industry, our business meetings help Pharma-Biotech to find new vendors, investors, & strategic partners.
Our poster presentations serve as a window for attendees to look at the latest breakthroughs of the company in a quick and organized manner in a few minutes.
Networking is our main priority, the default and organic way to connect with people of interest.
Strategies for building a sustainable drug discovery infrastructure
9:00 - 9:25 AMAI-enhanced Drug Design & Development: towards a Computational Precision Medicine
9:25 - 9:50 AMReserved for Sponsor Presentation
9:50 - 10:15 AMFragment-Based Drug Design: Advancing Tools and Technologies
10:15 - 10:40 AMPhenotypic Screening in Drug Discovery and High Content Screening Tools
11:10 - 11:35 AMImportance of Data Centricity
11:35 - 12:05 PMADCs: a New Class of Drugs Designed as a Targeted Therapy for Cancer
12:05 - 12:30 PMAccelerating Drug Discovery Research using High-Content Screening Technology
12:30 - 12:55 PMDrug Repurposing (DR): An Emerging Approach in Drug Discovery
12:55 - 01:20 PMReserved for Sponsor Presentation
02:20 - 02:45 PMData Visualization to accelerate biological discovery
02:45 - 03:10 PMAdvanced Bioinformatics Techniques for Biologics Drug Discovery
03:10 - 03:35 PMPredicting Drug Toxicity
03:35 - 04:00 PMIsotopic Labeling of Metabolites in Drug Discovery applications
04:30 - 04:55 PMDrug Discovery of New Modalities: Lead Optimization of Peptides and Oligonucleotides
9:00 - 9:25 AMThe Importance of Collaborative Business Models for Drug Development
9:25 - 9:50 AMReserved for Sponsor Presentation
9:50 - 10:15 AMTargets, translation & risk: Conceptual Framework for Drug Discovery Decision Making
10:15 - 10:40 AMHarnessing DNA Encoded Libraries
11:10 - 11:35 AMImportance of Animal Models & emerging alternatives
11:35 - 12:05 PMThe Organ-On-A-Chip platform for disease modelling and therapeutic screening
12:05 - 12:30 PMRNA optimization is a powerful tool for drug discovery
12:30 - 12:55 PMBenefits, limitations, and diversity of AI models in Drug and Target Discovery
12:55 - 01:20 PMReserved for Sponsor Presentation
02:20 - 02:45 PMBiomarkers in DD and development: from target identification through drug marketing
02:45 - 03:10 PMChallenges and opportunities for collaboration and Data sharing
03:10 - 03:35 PMNovel approaches for cell & gene therapy – Evolution or Revolution
03:35 - 04:00 PMIncreasing efficacy in target identification and validation
04:30 - 04:55 PMAn exclusive audience from growth stage pharma-biotech companies
Maximize ROI for time and investment; we Deliver what we Commit
Experienced executives providing a Premium Experience
Well researched and implementable Knowledge shared by Industry Leaders
Choose your favorite pass for the event.
This list Represents Previous and Current Sponsors.
These are three top picks from our side, check the full list here:
If you have any questions about the event, please contact us directly. We will respond for sure.
